التفاصيل البيبلوغرافية
| العنوان: |
Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment? |
| المؤلفون: |
Lenneman, Carrie G.1,2 carrie.lenneman@louisville.edu, Abdallah, Wissam M.1, Smith, Holly M.1, Abramson, Vandana1, Mayer, Ingrid A.1, Silverstein, Cheri1,3, Means-Powell, Julie1, Paranjape, Sachin Y.1, Lenihan, Daniel1, Sawyer, Douglas B.1,4, Raj, Satish R.1,4 |
| المصدر: |
Ecancermedicalscience. 2014, Vol. 8 Issue 413-446, p1-9. 9p. |
| مصطلحات موضوعية: |
*SYMPATHETIC nervous system, *HER2 protein, *TRASTUZUMAB, *BREAST cancer patients, *NORADRENALINE, *CATECHOLAMINES, *THERAPEUTICS |
| مستخلص: |
Background: HER2 antagonists (anti-HER2; e.g., trastuzumab and lapatinib) are effective in treating an aggressive form of breast cancer (BC), but can cause cardiotoxicity due to the disruption in neuregulin (NRG)/HER2+ ligand receptor signalling. The recent data show that NRG-HER2 receptors located in the medulla oblongata are important regulators of vasomotor tone. Disrupting the NRG-HER2 signalling in mouse medulla results in increased sympathetic nerve output and blood pressure. We hypothesized that anti-HER2 agents would cause increased sympathetic tone with changes in plasma catecholamines and NRG. Methods: In 15 newly diagnosed HER2+ BC patients receiving anti-HER2 agents, vital signs were measured along with supine plasma epinephrine (EPI), norepinephrine (NE), and NRG at baseline and three months. Serial echocardiography was performed. Results: With three months of anti-HER2 treatment, NE increased (2.334 ± 1.294 nmol/L vs. 3.262 ± 2.103 nmol/L; p = 0.004) and NRG decreased (12.7±15.7 ng/ml vs. 10.9 ± 13.3 ng/ml; p = 0.036) with a corresponding increase in systolic blood pressure (110 ± 10 mmHg vs. 120 ± 16 mmHg, p = 0.049) and diastolic blood pressure (67 ± 14 vs. 77 ± 10, p = 0.009). There was no change, however, in EPI (0.183 ± 0.151 nmol/L vs. 0.159 ± 0.174 nmol/L; p = 0.519) or heart rate (73 ± 12 bpm vs. 77 ± 10 bpm, p = 0.146). Left ventricular ejection function declined over the follow-up period (baseline 63 ± 6% vs. follow-up 56 ± 5%). Conclusions: Anti-HER2 treatment results in increased NE, blood pressure, and decreased NRG; this suggests that the inhibition of NRGHER2 signalling leads to increased sympathoneural tone. Larger studies are needed to determine if these observations have prognostic value and may be offset with medical interventions, such as beta-blockers. Clinical Trial Registration: The study was registered with www.clinicaltrials.gov (NCT00875238). [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder